Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Avidity Biosciences Inc
RNACurrent price
26.66 USD
+0.9 USD (+3.49%)
Last closed
25.48 USD
Company
www.aviditybiosciences.com
ISIN
US05370A1088
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
3 204 851 968 USD
Yield for 12 month
+10.35 %
1Y
3Y
5Y
10Y
15Y
RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial. Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpacibart braxlosiran for the treatment of facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare genetic cardiomyopathies for PRKAG2 syndrome and PLN cardiomyopathy. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. Address: 10578 Science Center Drive, San Diego, CA, United States, 92121
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
66.69 USDP/E ratio
–Dividend Yield
–Current Year
+10 897 000 USD
Last Year
+9 560 000 USD
Current Quarter
+2 973 000 USD
Last Quarter
+2 336 000 USD
Current Year
+10 897 000 USD
Last Year
+7 459 000 USD
Current Quarter
+2 973 000 USD
Last Quarter
+2 336 000 USD
Key Figures RNA
1 year
3 years
5 years
10 years
EBITDA
-376 160 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-21.61 %
PEG Ratio
–
Return On Equity TTM
-33.47 %
Wall Street Target Price
66.69 USD
Revenue TTM
10 897 000 USD
Book Value
11.89 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
35.60 %
Dividend Yield
–
Gross Profit TTM
-292 696 000 USD
Earnings per share
-2.99 USD
Diluted Eps TTM
-2.99 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics RNA
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History RNA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation RNA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
156.94
Price Sales TTM
294.10
Enterprise Value EBITDA
-5.72
Price Book MRQ
2.25
Financials RNA
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators RNA
For 52 weeks
21.51 USD
56.00 USD
50 Day MA
30.11 USD
Shares Short Prior Month
16 128 099
200 Day MA
38.10 USD
Short Ratio
12.02
Shares Short
17 574 901
Short Percent
18.00 %
BeatStart